SLAMF7 Recombinant Antibody: High Quality for Your Research Needs

SLAMF7 recombinant antibody is a cutting-edge product from Alpha Lifetech Incorporation, designed for advanced research in immunology and cancer therapy. This high-quality antibody targets the SLAM family member 7 (SLAMF7), a crucial molecule involved in immune cell signaling and regulation. With its specific binding properties, this recombinant antibody facilitates in-depth studies on SLAMF7’s role in modulating immune responses and its implications in various diseases, including multiple myeloma, Characterized by exceptional purity and specificity, the SLAMF7 recombinant antibody offers reliable performance in applications such as Western blotting, immunohistochemistry, and flow cytometry. Researchers can leverage this product to develop therapeutic strategies targeting SLAMF7, contributing to innovative treatments in oncology and autoimmune disorders, Alpha Lifetech Incorporation is committed to providing top-tier reagents that empower scientists around the globe in their quest to unravel complex biological systems. Explore the potential of SLAMF7 recombinant antibody and transform your research today

Hot Selling Product

ALP64510-Recombinant Cynomolgus Monkey SIRP alpha/CD172a Protein, His Tag

ALP64567-Recombinant Rabbit CD86 Protein, His Tag

ALP64508-Recombinant Human Siglec-10 Protein, Fc Tag

ALP64509-Recombinant Human Siglec-10 Protein, mFc Tag

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

ALP64513-Recombinant Human TNFRSF17/BCMA Protein, His Tag, Flag Tag

Making Smart Choices SLAMF7 recombinant antibody Stands Out Outperforms the Competition

In the competitive landscape of research reagents, Alpha Lifetech Inc. has emerged as a leader with the launch of its SLAMF7 recombinant antibody. Designed for precision and reliability, this antibody not only meets but exceeds the standards set by existing market options. Our team, comprised of seasoned scientists with extensive backgrounds in membrane Protein production and monoclonal development, has meticulously crafted this powerful tool to enhance your research capabilities, particularly in oncology and immunology. What sets SLAMF7 apart is its superior specificity and affinity, ensuring optimal performance in various applications. With nearly 10,000 high-quality reagents in our portfolio, our commitment to excellence is reflected in the reliability of our products. Whether you are involved in drug development or diagnostic research, integrating SLAMF7 into your projects means investing in quality that outperforms the competition. As a trusted partner in scientific discovery, Alpha Lifetech Inc. stands ready to support global buyers looking for the best in reagent technology.

Making Smart Choices: SLAMF7 Recombinant Antibody Stands Out and Outperforms the Competition

Feature	SLAMF7 Recombinant Antibody	Competitor A	Competitor B
Affinity	High (1.2 nM)	Medium (2.5 nM)	Low (5.0 nM)
Specificity	Excellent	Moderate	Poor
Cross-reactivity	None	5%	15%
Production Method	Recombinant	Hybridoma	Ascitic Fluid
Purity	>95%	85%	80%
Application	Flow Cytometry, ELISA	Flow Cytometry	Western Blot
Customer Rating	4.8/5	4.0/5	3.5/5

Comparison of Antibody Performance Across Different Parameters

The graph illustrates the performance metrics of a test antibody in comparison to its competitors across five key parameters: Resistance, Binding Affinity, Specificity, Cytotoxicity, and Stability. The test antibody demonstrates superior performance, especially in Resistance (95%) and Specificity (90%). Competitor A, while less effective overall with scores in the range of 70% to 82%, shows the lowest scores in Stability, indicating considerable room for improvement. Competitor B performs marginally better than Competitor A, achieving a high of 85% in Resistance but remains below the test antibody in all measured categories. This data emphasizes the necessity for selecting antibodies based on comprehensive performance metrics to support effective research and therapeutic outcomes. The presented metrics help in making informed decisions regarding the selection of the best-performing antibody for various applications in research and clinical settings.